This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Hodgkin's disease

Authoring team

First described by Sir Thomas Hodgkin in 1832 Hodgkin lymphoma (HL) is a malignant proliferation of the lymphoid system.

  • the disease is characterised by the presence of multinucleated giant cells (Hodgkin and Reed-Sternberg - HRS) within a cellular infiltrate of non-malignant inflammatory cells that make up the majority of the tumour tissue on histological examination (1)
  • HRS cells have been identified clonal B cells that lack typical B-cell surface antigens (1)

HL can be classified as:

  • nodular lymphocyte predominant Hodgkin Lymphoma (NLPHL)
    • represents about 5% of all cases of the disease
    • HRS cells are not present
  • classical HL - this is further dived into four sub-types
    • nodular sclerosis - accounts for 70% of all classical HL
    • mixed cellularity
    • lymphocyte-rich
    • lymphocyte-depleted (1)

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.